Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.

被引：0
|
作者：
Bello, Carlo [1 ]
Brar, Satjit [1 ]
Masters, Joanna C. [2 ]
Khandelwal, Akash [3 ]
Novakovic, Ana M. [3 ]
Ruiz-Garcia, Ana [1 ]
Hibma, Jennifer [2 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, La Jolla, CA USA
[3] Merck KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364
引用
收藏
页数：2
相关论文
共 50 条
  • [1] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [2] Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Miyake, Hideaki
    Uemura, Hirotsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Wang Jing
    Mariani, Mariangela
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Uemura, Motohide
    Tomita, Yoshihiko
    Miyake, Hideaki
    Hatakeyama, Shingo
    Kanayama, Hiro-omi
    Numakura, Kazuyuki
    Takagi, Toshio
    Kato, Tomoyuki
    Eto, Masatoshi
    Obara, Wataru
    Uemura, Hirotsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Oya, Mototsugu
    CANCER SCIENCE, 2020, 111 (03) : 907 - 923
  • [7] C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Uemura, Hirotsugu
    Oya, Mototsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Huang, Bo
    Di Pietro, Alessandra
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Efficacy of avelumab plus axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
    Haanen, John
    Larkin, James
    Choueiri, Toni
    Albiges, Laurence
    Rini, Brian
    Atkins, Michael
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    di Pietro, Alessandra
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 51 - 51
  • [9] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345